COVID-19
Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.
The Lancet Commission published a lengthy criticism of the WHO’s COVID-19 pandemic response. In turn, the WHO offered a reply to a number of the complaints.
A collaborative team of scientists formed The Long COVID Research Initiative to study and treat those battling the long-term effects of the virus, which include serious mental and physical symptoms.
Researchers at the Wuhan Institute of Virology (WIV), which is potentially linked to the origins of COVID-19, reported the discovery of a novel DNA virus in animals in the journal Virologica Sinica.
Moderna announced it is filing lawsuits against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccine infringes patents covering its mRNA technology.
According to a recent study, Pfizer’s Paxlovid appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients suffering from the Omicron variant of COVID-19.
In an interview with Reuters, AstraZeneca CEO Pascal Soriot said Tuesday that he isn’t sure if the company will continue developing vaccines. He also hinted at potential M&A action.
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
PRESS RELEASES